Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 519 (2) , 267-273
Abstract
No abstract availableKeywords
Funding Information
- National Basic Research Program of China (2015CB931800)
- Shanghai Association for Science and Technology (18431902800)
- National Natural Science Foundation of China (81773620, 81573332, 31872746)
This publication has 31 references indexed in Scilit:
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- Pharmaceutical Aspects of the Recombinant Human Serum Albumin Dimer: Structural Characteristics, Biological Properties, and Medical ApplicationsJournal of Pharmaceutical Sciences, 2012
- Competitive Selection from Single Domain Antibody Libraries Allows Isolation of High-Affinity Antihapten Antibodies That Are Not Favored in the llama Immune ResponseAnalytical Chemistry, 2011
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumorsBMC Cancer, 2010
- Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastorisJournal of Biotechnology, 2010
- Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended DerivativesJournal of Biological Chemistry, 2009
- Select what you need: A comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genesJournal of Biotechnology, 2007
- Expression of an anti-CD33 single-chain antibody by Pichia pastorisJournal of Immunological Methods, 2005
- AlbuminHepatology, 2005